Page 313 - Drug Class Review
P. 313
Drug Effectiveness Review Project
galantamine placebo NR for subgroup NR for subgroup 10.3% 19.7% Post randomization exclusions: Yes Overall loss to follow-up: 135 (23%) Loss to follow-up differential high: No placebo galantamine 17% 26% 8% 20% Page 187 of 205
NR ITT: Yes Yes Yes Yes Fair
Final Report Update 1 Authors: Erkinjuntti et al. Year: 2002 ADVERSE EVENTS: Overall adverse effects reported: Nausea for AD subgroup • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
